- Safety & Recalls
- Regulatory Updates
- Drug Coverage
- COPD
- Cardiovascular
- Obstetrics-Gynecology & Women's Health
- Ophthalmology
- Clinical Pharmacology
- Pediatrics
- Urology
- Pharmacy
- Idiopathic Pulmonary Fibrosis
- Diabetes and Endocrinology
- Allergy, Immunology, and ENT
- Musculoskeletal/Rheumatology
- Respiratory
- Psychiatry and Behavioral Health
- Dermatology
- Oncology
First-time generic approvals, November 2007
First-time generic approvals: oxcarbazepine tablets; risedronate tablets; clarithromycin for oral suspension
Key Points
Oxcarbazepine tablets, 150, 300, and 600 mg (equiv to Trileptal tablets)
ROXANE, GLENMARK, SUN
Risedronate tablets, 5, 30, and 35 mg (equiv to Actonel tablets)
Clarithromycin for oral suspension, 125 mg/5 mL and 250 mg/5 mL (equiv to Biaxin Granules for oral suspension)
RANBAXY
FDA Approves Pfizer’s Gene Therapy for Beqvez for Hemophilia
April 26th 2024Beqvez (fidanacogene elaparvovec) is priced at $3.5 million, which is on parity with Hemgenix, the first one-time therapy to treat adults with hemophilia B. Pfizer’s warranty will refund insurers and continue to provide coverage for patients if they change insurers.
FDA Issues Complete Response Letter for Pz-Cel to Treat Epidermolysis Bullosa
April 22nd 2024Prademagene zamikeracel is a cell therapy designed to incorporate the functional collagen-producing COL7A1 gene into a patient’s own skin cells. The FDA is asking for additional information on manufacturing practices.
